This content is from: Premium
Trouble in IPO Land
The shares of several companies that recently went public are down by double-digit percentages from their official pricing.
A fledgling biopharma company that went public last week with at least a half dozen hedge fund investors has seen its stock mauled in its first two trading days.Pyxis Oncology Thursday priced its initial public offering of 10.5 million shares at $16 per share.The stock then plunged 17.5 percent to
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.